{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:11:03Z","timestamp":1788012663895,"version":"build-2784847793"},"reference-count":20,"publisher":"Japanese Circulation Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2024,9,25]]},"DOI":"10.1253\/circj.cj-23-0954","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T22:17:01Z","timestamp":1716848221000},"page":"1672-1678","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants for Japanese Patients With Venous Thromboembolism\u3000\u2015 The Primary Results From the KUROSIO Study \u2015"],"prefix":"10.1253","volume":"88","author":[{"given":"Norikazu","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Cardiology, Kuwana City Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tamaru","sequence":"additional","affiliation":[{"name":"Clinical Research Support Center, Mie University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihisa","family":"Umetsu","sequence":"additional","affiliation":[{"name":"Division of Vascular Surgery, Department of Surgery, Tohoku University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ohashi Hospital, Toho University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuyuki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Hospital Organization Okayama Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Yuzaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Wakayama Saiseikai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Clinical Research Support Center, Mie University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Ogura","sequence":"additional","affiliation":[{"name":"Clinical Research Support Center, Mie University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Intensive Care, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirono","family":"Satokawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Fukushima Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Obayashi","sequence":"additional","affiliation":[{"name":"Faculty of Health Science, Gunma Paz University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashio","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Hidamarinooka Nakamura Medical Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of KUROSIO Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies. <i>Thromb J<\/i> 2013; 11: 21.","DOI":"10.1186\/1477-9560-11-21"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. <i>N Engl J Med<\/i> 2013; 369: 799\u2013808.","DOI":"10.1056\/NEJMoa1302507"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hokusai-VTE Investigators; B\u00fcller HR, D\u00e9cousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. <i>N Engl J Med<\/i> 2013; 369: 1406\u20131415.","DOI":"10.1056\/NEJMoa1306638"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. <i>N Engl J Med<\/i> 2010; 363: 2499\u20132510.","DOI":"10.1056\/NEJMoa1007903"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. EINSTEIN-PE Investigators; Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. <i>N Engl J Med<\/i> 2012; 366: 1287\u20131297.","DOI":"10.1056\/NEJMoa1113572"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, et al. Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report. <i>Chest<\/i> 2021; 160: e545\u2013e608.","DOI":"10.1016\/j.chest.2021.07.055"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>Eur Heart J<\/i> 2020; 54: 543\u2013603.","DOI":"10.1183\/13993003.01647-2019"},{"key":"8","unstructured":"8. JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2017) (in Japanese). https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2017\/09\/JCS2017_ito_h.pdf (accessed August 22, 2023)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yamashita Y, Morimoto T, Yoshikawa Y, Yaku H, Sumita Y, Nakai M, et al. Temporal trends in the practice pattern for venous thromboembolism in Japan: Insight from JROAD-DPC. <i>J Am Heart Assoc<\/i> 2020; 9: e014582.","DOI":"10.1161\/JAHA.119.014582"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Takahashi S, Imura M, Katada J. Epidemiology and treatment patterns of venous thromboembolism: An observational study of nationwide time-series trends in Japan. <i>Cardiol Ther<\/i> 2022; 11: 589\u2013609.","DOI":"10.1007\/s40119-022-00284-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yamada N, Hirayama A, Maeda H, Satoru S, Hiroo S, Martin HP, et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism: The J-EINSTEIN DVT and PE program. <i>Thromb J<\/i> 2015; 13: 2.","DOI":"10.1186\/s12959-015-0035-3"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nakamura M, Nishikawa M, Komuro I, Kitajima I, Uetsuka Y, Yamagami T, et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). <i>Circ J<\/i> 2015; 79: 1230\u20131236.","DOI":"10.1253\/circj.CJ-15-0195"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nakamura M, Miyata T, Ozeki Y, Takayama M, Komori K, Yamada N, et al. Current venous thromboembolism management and outcomes in Japan. <i>Circ J<\/i> 2014; 78: 708\u2013717.","DOI":"10.1253\/circj.CJ-13-0886"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yamada N, Mo M, Ohsawa A, Sato M, Umeyama M, Shima D, et al. Safety and effectiveness of apixaban in Japanese patients with venous thromboembolism in clinical practice: A post-marketing surveillance. <i>Circ J<\/i> 2021; 85: 2201\u20132207.","DOI":"10.1253\/circj.CJ-20-0829"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nakamura M, Yamada N, Asamura T, Shiosakai K, Uchino K. Safety and effectiveness of edoxaban in Japanese venous thromboembolism patients: Final analysis of one-year follow-up data from a Japanese postmarketing observational study (ETNA-VTE-Japan). <i>Circ Rep<\/i> 2020; 2: 192\u2013202.","DOI":"10.1253\/circrep.CR-19-0127"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Okumura Y, Fukuda I, Nakamura M, Yamada N, Takayama M, Maeda H, et al. A multicenter prospective observational cohort study to investigate the effectiveness and safety of rivaroxaban in Japanese venous thromboembolism patients (The J\u2019xactly Study). <i>Circ J<\/i> 2020; 84: 1912\u20131921.","DOI":"10.1253\/circj.CJ-20-0636"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Campia U. Vascular effects of cancer treatments. <i>Vasc Med<\/i> 2020; 25: 226\u2013234.","DOI":"10.1177\/1358863X20914978"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tsoukalas N, Brito-Dellan N, Font C, Butler T, Rojas-Hernandez CM, Butler T. Complexity and clinical significance of drug\u2013drug interactions (DDIs) in oncology: Challenging issues in the care of patients regarding cancer-associated thrombosis (CAT). <i>Support Care Cancer<\/i> 2022; 30: 8559\u20138573.","DOI":"10.1007\/s00520-022-07235-8"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Wang TF. Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer. <i>Thromb Res<\/i> 2022; 213: S66\u2013S67.","DOI":"10.1016\/j.thromres.2021.11.026"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, et al. Anticoagulation therapy for venous thromboembolism in the real world: From the COMMAND VTE registry. <i>Circ J<\/i> 2018; 82: 1262\u20131270.","DOI":"10.1253\/circj.CJ-17-1128"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/88\/10\/88_CJ-23-0954\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T03:22:53Z","timestamp":1727493773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/88\/10\/88_CJ-23-0954\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-23-0954","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,25]]},"article-number":"CJ-23-0954"}}